Researchers from The University of Manchester and The Christie NHS Foundation Trust — both part of Manchester Cancer Research Centre — say the test could be developed and used in hospitals within the next few years. …
These interim results of the 5-year Phase II clinical trial using the experimental regimen are being presented at the Breast Cancer Symposium 2014 in San Francisco by Anthony E. Dragun, M.D., vice chair and associate professor of radiation oncology at the University of Louisville. Dragun, a radiation oncologist with University of Louisville Physicians, launched the trial three years ago at UofL’s James Graham Brown Cancer Center, a part of KentuckyOne Health and the only site offering the experimental regimen in the United States…
When added to the standard chemotherapy treatment — fluorouracil and leucovorin — adjuvant irinotecan therapy improved overall survival rates for patients with the CpG island methylator phenotype (CIMP). CIMP is seen in about 10 to 20 percent of colorectal cancers…
EGFR tyrosine kinase inhibitor (TKI) therapy is approved for EGFR activating mutation positive patients with advanced NSCLC, but the standard for determining mutation status is with DNA derived directly from tumor tissue, which can be limited or not available. …
The drug, known under the brand name Nanotax, is a fine particle reformulation of paclitaxel, the standard treatment for ovarian cancer. …
Every year 8,800 people are diagnosed with the disease in the UK but survival rates remain very low, with only three per cent of people diagnosed with pancreatic cancer surviving their disease for five years or more after their diagnosis. Cancer Research UK has made pancreatic cancer research a priority, and has the bold ambition to more than double its annual spend of £6million on research into the disease over the next five years. The charity is investing in fundamental biology investigating how the cancer spreads as well as trials looking at boosting the effectiveness of the standard chemotherapy treatments in pancreatic cancer patients. While more research is needed to find better ways of diagnosing and treating the disease, there is evidence to suggest that some pancreatic cancers are linked to being overweight and to smoking — and almost four in 10 could be prevented by lifestyle changes to address this…
source : http://www.sciencedaily.com/releases/2014/05/140529132004.htm
source : http://www.sciencedaily.com/releases/2014/05/140521133838.htm
source : http://www.sciencedaily.com/releases/2014/05/140522175717.htm
source : http://www.sciencedaily.com/releases/2014/05/140512101911.htm